About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

GSK's Offer of 50% Discount on Pills Was a "Mistake"; Press Release Published in Error

By Jim Edwards | May 8, 2009

GlaxoSmithKline put out a press release offering a 50 percent price cut on all their medicines to anyone without insurance, regardless of income — but the release was a mistake and the company has retracted the statement. The statement was made-up to test a PR distribution system. But then every PR rep’s worst nightmare happened: A fake release full of bogus (and potentially costly) information made its way into the media.

You can read the original press release here. It said:

Beginning April 1, GlaxoSmithKline (NYSE: GSK) will offer a 50 percent discount on its medicines to patients younger than 65 years old who lack prescription drug insurance, regardless of their income.

It’s not an April Fool’s joke, despite the date. Fierce Pharma reports:

The release “was a test publication which was accidentally distributed through PRWeb,” according to the manager. “We are currently in the process of retraction for Comtex and TradingMarkets.com. Needless to say, GlaxoSmithKline is extremely unhappy about this.”

The release even disclosed a website, gsksavings.com, which is inactive but is actually owned by GSK.

There were some clues that the release was questionable. It was riddled with question marks in parentheses, as if information still needed to be checked, and several dollar numbers were represented only by “xxxx.”

And the release gives us a little insight into either the way GSK would like to see itself, or the way the writer would like to see GSK. In addition to the fictional discount, GSK was to offer uninsured patients a fictional “health coach, a health care professional (??) who can provide free disease information via telephone.” Predictably, the fictional largesse was met with fictional joy among the fictional uninsured:

Evelyn White, Owner, SalonStyle in Poughkeepsie, NY
‘As a small business owner with a preexisting condition, I really appreciate finally having a resource like the Prescription Cost Relief Card.’

There is, of course, no SalonStyle in Poughkeepsie.

GSK says confused patients have already started contacting the company looking for the medicine discount. A PRWeb rep explained how the error happened:

“The erroneously distributed content was the product of a demo for GSK itself” said a PRWeb spokesperson. ”The copy was produced just to demonstrate what a finished-product distribution would look like through our system, but it was engineered cooperatively by a GSK representative and one of our salespersons. However, it was our newswire (PRWeb.com) that initially distributed; from us to Comtex, Pheedo, Topix, and AOL, and from there to everywhere else.”

So, er, the system works, then? It’s just the humans who are faulty.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Glaxo Knew Avandia Diabetes Drug Caused Heart Risk, Report Says

    BusinessWeek - 23 days 18 hours 47 minutes ago

    Feb. 20 (Bloomberg) -- GlaxoSmithKline Plc knew its diabetes drug Avandia might cause heart damage several years before a study documented the risk and the company pressed doctors to retract or revise warnings about side effects, said a report from researchers for the U.S. Senate Finance Committee.Avandia came on the market in 1999 and achieved...

  • Glaxo Falls on U.S. Report Over Avandia’s Heart Risk (Update1)

    BusinessWeek - 21 days 23 hours 17 minutes ago

    Feb. 22 (Bloomberg) -- GlaxoSmithKline Plc shares fell after a report from two U.S. senators raised concern that the drugmaker may be more vulnerable to lawsuits over the risk that its Avandia diabetes medicine causes heart attacks.Glaxo knew Avandia may cause heart damage several years before a study documented the risk and the company pressed...

  • Senators Release Report On Avandia

    Forbes - 23 days 21 hours 35 minutes ago

    The Senate Finance Committee has released a detailed report of its investigations into how the Food and Drug Administration and GlaxoSmithKline handled research into whether the diabetes drug Avandia increases the risk of heart attacks. Neither the FDA nor Glaxo comes out looking very good. A press release, the report, and a letter Senators...

  • XenoPort cuts 50% of workforce

    FierceBiotech - 7 days 22 hours 23 minutes ago

    In a terse announcement released Friday, Santa Clara, CA-based XenoPort said it's cutting 50 percent of its 219-person staff and refocusing its development efforts on its late-stage product candidates. The decision follows the FDA's February 18 rejection of XenoPort and GlaxoSmithKline's application for Horizant, an experimental restless leg...

  • GSK's RLS setback has XenoPort halving workforce

    Scrip News - 6 days 21 hours 42 minutes ago

    XenoPort is shedding 50% of its workforce and shelving its discovery research efforts following the "unexpected setback" in the approval of Horizant (XP13512; gabapentin enacarbil extended release tablets), which is under development with GlaxoSmithKline in the US to treat restless legs syndrome

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a>)

advertisement
advertisement
advertisement